{"id":"https://openalex.org/W2013603308","doi":"https://doi.org/10.1097/00004850-198701000-00005","title":"Anticholinergic Equivalents and Parkinsonism: A Model for Predicting Side-effects of Anti psychotic Drugs","display_name":"Anticholinergic Equivalents and Parkinsonism: A Model for Predicting Side-effects of Anti psychotic Drugs","publication_year":1987,"publication_date":"1987-01-01","ids":{"openalex":"https://openalex.org/W2013603308","doi":"https://doi.org/10.1097/00004850-198701000-00005","mag":"2013603308","pmid":"https://pubmed.ncbi.nlm.nih.gov/2889760"},"language":"en","primary_location":{"id":"doi:10.1097/00004850-198701000-00005","doi":"https://doi.org/10.1097/00004850-198701000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-198701000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083369404","display_name":"David Benjamin Menkes","orcid":"https://orcid.org/0000-0003-3760-7896","observed_orcids":["https://orcid.org/0000-0003-3760-7896"]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"DAVID B. MENKES","raw_affiliation_strings":["Department of Psychological Medicine, University of Otago, Dunedin, New Zealand","The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychological Medicine, University of Otago, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000451180","display_name":"Hugh Clarkson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"HUGH O. CLARKSON","raw_affiliation_strings":["The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064655139","display_name":"GlLLlAN CARADOC-DAVIES","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"GlLLlAN CARADOC-DAVIES","raw_affiliation_strings":["The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110854993","display_name":"Paul E. Mullen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"PAUL E. MULLEN","raw_affiliation_strings":["The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Neuroscience Centre and Department of Psychological Medicine, University of Otago, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I80281795"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.13597804,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"2","issue":"1","first_page":"55","last_page":"67"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8090000152587891},{"id":"https://openalex.org/keywords/antimuscarinic-activity","display_name":"antimuscarinic activity","score":0.8090000152587891},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.859000027179718},{"id":"https://openalex.org/keywords/parkinsonism","display_name":"parkinsonism","score":0.8209999799728394},{"id":"https://openalex.org/keywords/antiparkinsonian-drugs","display_name":"antiparkinsonian drugs","score":0.7770000100135803},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.9440000057220459}],"concepts":[{"id":"https://openalex.org/C2910393698","wikidata":"https://www.wikidata.org/wiki/Q415026","display_name":"Benztropine","level":3,"score":0.9546328186988831},{"id":"https://openalex.org/C2778689640","wikidata":"https://www.wikidata.org/wiki/Q113259","display_name":"Anticholinergic","level":2,"score":0.9476073384284973},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.7584377527236938},{"id":"https://openalex.org/C3019878999","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic drug","level":4,"score":0.6410520076751709},{"id":"https://openalex.org/C2780688371","wikidata":"https://www.wikidata.org/wiki/Q58375","display_name":"Thioridazine","level":3,"score":0.5932608842849731},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5637126564979553},{"id":"https://openalex.org/C2910745098","wikidata":"https://www.wikidata.org/wiki/Q113259","display_name":"Anticholinergic agents","level":3,"score":0.5591593384742737},{"id":"https://openalex.org/C2910202354","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic Agent","level":4,"score":0.5282995700836182},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5196655988693237},{"id":"https://openalex.org/C2779406339","wikidata":"https://www.wikidata.org/wiki/Q2991856","display_name":"Trihexyphenidyl","level":2,"score":0.4857211709022522},{"id":"https://openalex.org/C2780616385","wikidata":"https://www.wikidata.org/wiki/Q1385411","display_name":"Extrapyramidal symptoms","level":4,"score":0.46591830253601074},{"id":"https://openalex.org/C2776525014","wikidata":"https://www.wikidata.org/wiki/Q1531991","display_name":"Parkinsonism","level":3,"score":0.4599529802799225},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4250360131263733},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.34803271293640137},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3384302258491516},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.236182302236557},{"id":"https://openalex.org/C2778775820","wikidata":"https://www.wikidata.org/wiki/Q407972","display_name":"Chlorpromazine","level":2,"score":0.23373880982398987},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.22356674075126648},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.10273778438568115},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.05443349480628967},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001590","descriptor_name":"Benztropine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001921","descriptor_name":"Brain","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010302","descriptor_name":"Parkinson Disease, Secondary","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D011950","descriptor_name":"Receptors, Cholinergic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D011976","descriptor_name":"Receptors, Muscarinic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013375","descriptor_name":"Substance Withdrawal Syndrome","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004850-198701000-00005","doi":"https://doi.org/10.1097/00004850-198701000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-198701000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:2889760","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2889760","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1973585598","https://openalex.org/W1972701023","https://openalex.org/W1989341269","https://openalex.org/W2084940402","https://openalex.org/W2485048345","https://openalex.org/W2082897784","https://openalex.org/W2036841195","https://openalex.org/W2067116914","https://openalex.org/W2048246392","https://openalex.org/W2123028409"],"abstract_inverted_index":{"The":[0,41,74],"tendency":[1],"of":[2,22,35,48,65],"antipsychotics":[3],"to":[4],"produce":[5],"extrapyramidal":[6],"side-effects":[7],"varies":[8],"inversely":[9],"with":[10,46,55],"their":[11,71],"antimuscarinic":[12,20,29,68],"activity.":[13],"This":[14],"paper":[15],"reviews":[16],"the":[17,27],"antipsychotic":[18,66,82],"and":[19,25,39,83,86],"potency":[21],"these":[23],"drugs":[24],"compares":[26],"total":[28,81],"activity":[30,69],"in":[31,51,70],"standard":[32],"daily":[33],"doses":[34],"antipsychotics,":[36],"antiparkinson":[37,92],"agents":[38],"antidepressants.":[40],"authors":[42],"examine":[43],"factors":[44],"associated":[45],"tolerance":[47],"benztropine":[49,60],"withdrawal":[50,61],"39":[52],"inpatients.":[53],"Patients":[54],"serious":[56],"EPS":[57],"relapse":[58],"after":[59],"had":[62],"an":[63,77],"excess":[64],"over":[67],"remaining":[72],"medications.":[73],"results":[75],"suggest":[76],"optimal":[78],"ratio":[79],"between":[80],"anticholinergic":[84],"doses,":[85],"a":[87],"simple":[88],"model":[89],"for":[90],"predicting":[91],"drug":[93],"requirements.":[94]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}